CU06-1004 not checked
Curacle Co., Ltd. · SAC-1004 · CU06
FollowEvery change as it happens, and a Monday email
Trials
1 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CU06-1004 is an oral capsule. At room temperature, it appears as a white to off-white powder. The 100 mg soft gelatin capsules contain a solution-based fill.”In the company’s words, NCT07459829 on ClinicalTrials.gov
- Tested for
- DME, Diabetic Macular Edema, Diabetic Macular Edema (DME)
- Main trialPhase 2
- “This phase 2b trial is a randomized, double-masked, parallel-group, multi-center study in approximately 156 patients with Diabetic Macular Edema to evaluate the efficacy and safety of CU06-1004 orally administered once daily for 24 weeks. The study will have a 1:1:1 randomization (CU06-1004 200mg: CU06-1004 300mg: Placebo).”In the company’s words, NCT07459829 on ClinicalTrials.gov
- Other names
- SAC-1004 · CU06 · CU06-RE · Riverstat
Other drugs for DME
Coming up1
- 1 Jan 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 1 Jan 2028 | Study of CU06-1004 in Patients With Daibetic Macular Edema | |
| Phase 2Completed | 31 May 2023 | The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME) | |
| Phase 1Completed | 2 Mar 2022 | First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026